Collaborative Study for Analysis of Subvisible Particles Using Flow Imaging and Light Obscuration: Experiences in Japanese Biopharmaceutical Consortium

The evaluation of subvisible particles, including protein aggregates, in therapeutic protein products has been of great interest for both pharmaceutical manufacturers and regulatory agencies. To date, the flow imaging (FI) method has emerged as a powerful tool instead of light obscuration (LO) due t...

Full description

Saved in:
Bibliographic Details
Published inJournal of pharmaceutical sciences Vol. 108; no. 2; pp. 832 - 841
Main Authors Kiyoshi, Masato, Shibata, Hiroko, Harazono, Akira, Torisu, Tetsuo, Maruno, Takahiro, Akimaru, Michiko, Asano, Yuuka, Hirokawa, Mai, Ikemoto, Keisuke, Itakura, Yukari, Iwura, Takafumi, Kikitsu, Aya, Kumagai, Takashi, Mori, Naoki, Murase, Hiroaki, Nishimura, Hirotaka, Oda, Atsushi, Ogawa, Taiichiro, Ojima, Takuma, Okabe, Shinji, Saito, Shuntaro, Saitoh, Satoshi, Suetomo, Hiroyuki, Takegami, Kazuhiro, Takeuchi, Momoko, Yasukawa, Hidehito, Uchiyama, Susumu, Ishii-Watabe, Akiko
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.02.2019
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The evaluation of subvisible particles, including protein aggregates, in therapeutic protein products has been of great interest for both pharmaceutical manufacturers and regulatory agencies. To date, the flow imaging (FI) method has emerged as a powerful tool instead of light obscuration (LO) due to the fact that (1) protein aggregates contain highly transparent particles and thereby escape detection by LO and (2) FI provides detailed morphological characteristics of subvisible particles. However, the FI method has not yet been standardized nor listed in any compendium. In an attempt to assess the applicability of the standardization of the FI method, we conducted a collaborative study using FI and LO instruments in a Japanese biopharmaceutical consortium. Three types of subvisible particle preparations were shared across 12 laboratories and analyzed for their sizes and counts. The results were compared between the methods (FI and LO), inter-laboratories, and inter-instruments (Micro Flow Imaging and FlowCam). We clarified the marked difference between the detectability of FI and LO when counting highly transparent protein aggregates in the preparations. Although FlowCam provided a relatively higher number of particles compared with MFI, consistent results were obtained using the instrument from the same manufacturer in all 3 samples.
AbstractList The evaluation of subvisible particles, including protein aggregates, in therapeutic protein products has been of great interest for both pharmaceutical manufacturers and regulatory agencies. To date, the flow imaging (FI) method has emerged as a powerful tool instead of light obscuration (LO) due to the fact that (1) protein aggregates contain highly transparent particles and thereby escape detection by LO and (2) FI provides detailed morphological characteristics of subvisible particles. However, the FI method has not yet been standardized nor listed in any compendium. In an attempt to assess the applicability of the standardization of the FI method, we conducted a collaborative study using FI and LO instruments in a Japanese biopharmaceutical consortium. Three types of subvisible particle preparations were shared across 12 laboratories and analyzed for their sizes and counts. The results were compared between the methods (FI and LO), inter-laboratories, and inter-instruments (Micro Flow Imaging and FlowCam). We clarified the marked difference between the detectability of FI and LO when counting highly transparent protein aggregates in the preparations. Although FlowCam provided a relatively higher number of particles compared with MFI, consistent results were obtained using the instrument from the same manufacturer in all 3 samples.
The evaluation of subvisible particles, including protein aggregates, in therapeutic protein products has been of great interest for both pharmaceutical manufacturers and regulatory agencies. To date, the flow imaging (FI) method has emerged as a powerful tool instead of light obscuration (LO) due to the fact that (1) protein aggregates contain highly transparent particles and thereby escape detection by LO and (2) FI provides detailed morphological characteristics of subvisible particles. However, the FI method has not yet been standardized nor listed in any compendium. In an attempt to assess the applicability of the standardization of the FI method, we conducted a collaborative study using FI and LO instruments in a Japanese biopharmaceutical consortium. Three types of subvisible particle preparations were shared across 12 laboratories and analyzed for their sizes and counts. The results were compared between the methods (FI and LO), inter-laboratories, and inter-instruments (Micro Flow Imaging and FlowCam). We clarified the marked difference between the detectability of FI and LO when counting highly transparent protein aggregates in the preparations. Although FlowCam provided a relatively higher number of particles compared with MFI, consistent results were obtained using the instrument from the same manufacturer in all 3 samples.The evaluation of subvisible particles, including protein aggregates, in therapeutic protein products has been of great interest for both pharmaceutical manufacturers and regulatory agencies. To date, the flow imaging (FI) method has emerged as a powerful tool instead of light obscuration (LO) due to the fact that (1) protein aggregates contain highly transparent particles and thereby escape detection by LO and (2) FI provides detailed morphological characteristics of subvisible particles. However, the FI method has not yet been standardized nor listed in any compendium. In an attempt to assess the applicability of the standardization of the FI method, we conducted a collaborative study using FI and LO instruments in a Japanese biopharmaceutical consortium. Three types of subvisible particle preparations were shared across 12 laboratories and analyzed for their sizes and counts. The results were compared between the methods (FI and LO), inter-laboratories, and inter-instruments (Micro Flow Imaging and FlowCam). We clarified the marked difference between the detectability of FI and LO when counting highly transparent protein aggregates in the preparations. Although FlowCam provided a relatively higher number of particles compared with MFI, consistent results were obtained using the instrument from the same manufacturer in all 3 samples.
Author Ogawa, Taiichiro
Kumagai, Takashi
Oda, Atsushi
Torisu, Tetsuo
Okabe, Shinji
Takegami, Kazuhiro
Nishimura, Hirotaka
Murase, Hiroaki
Mori, Naoki
Akimaru, Michiko
Kiyoshi, Masato
Saitoh, Satoshi
Itakura, Yukari
Saito, Shuntaro
Shibata, Hiroko
Hirokawa, Mai
Ishii-Watabe, Akiko
Maruno, Takahiro
Iwura, Takafumi
Harazono, Akira
Kikitsu, Aya
Takeuchi, Momoko
Yasukawa, Hidehito
Asano, Yuuka
Suetomo, Hiroyuki
Ojima, Takuma
Ikemoto, Keisuke
Uchiyama, Susumu
Author_xml – sequence: 1
  givenname: Masato
  surname: Kiyoshi
  fullname: Kiyoshi, Masato
  organization: Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-9501, Japan
– sequence: 2
  givenname: Hiroko
  surname: Shibata
  fullname: Shibata, Hiroko
  email: h-shibata@nihs.go.jp
  organization: Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-9501, Japan
– sequence: 3
  givenname: Akira
  surname: Harazono
  fullname: Harazono, Akira
  organization: Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-9501, Japan
– sequence: 4
  givenname: Tetsuo
  surname: Torisu
  fullname: Torisu, Tetsuo
  organization: Vaccine Operations, Global Vaccine Business Unit, Takeda Pharmaceutical Company Limited, 4720 Takeda, Mitsui, Hikari, Yamaguchi 743-0011, Japan
– sequence: 5
  givenname: Takahiro
  surname: Maruno
  fullname: Maruno, Takahiro
  organization: U-Medico Inc., 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan
– sequence: 6
  givenname: Michiko
  surname: Akimaru
  fullname: Akimaru, Michiko
  organization: Analytical and Quality Evaluation Research Laboratories, Daiichi Sankyo Co., Ltd., 1-12-1, Shinomiya, Hiratsuka, Kanagawa 254-0014, Japan
– sequence: 7
  givenname: Yuuka
  surname: Asano
  fullname: Asano, Yuuka
  organization: Research Division, Formulation Development, Biomanufacturing Technology, JCR Pharmaceuticals Co., Ltd., 2-2-9 Murotani, Nishi-ku, Kobe, Hyogo 651-2241, Japan
– sequence: 8
  givenname: Mai
  surname: Hirokawa
  fullname: Hirokawa, Mai
  organization: Supply Chain Management Division, Pharmaceutical Research Department, Production Technology, Mitsubishi Tanabe Pharma Corporation, 3-16-89, Kashima, Yodogawa-ku, Osaka-shi, Osaka 532-8505, Japan
– sequence: 9
  givenname: Keisuke
  surname: Ikemoto
  fullname: Ikemoto, Keisuke
  organization: Supply Chain Management Division, Pharmaceutical Research Department, Production Technology, Mitsubishi Tanabe Pharma Corporation, 3-16-89, Kashima, Yodogawa-ku, Osaka-shi, Osaka 532-8505, Japan
– sequence: 10
  givenname: Yukari
  surname: Itakura
  fullname: Itakura, Yukari
  organization: Biologics and New Modalities Development, Pharmaceutical Sciences, Takeda Pharmaceutical Company Limited, 4720 Takeda, Mitsui, Hikari, Yamaguchi 743-0011, Japan
– sequence: 11
  givenname: Takafumi
  surname: Iwura
  fullname: Iwura, Takafumi
  organization: Bio Process Research and Development Laboratories, Kyowa Hakko Kirin Co., Ltd., 100-1, Hagiwara-machi, Takasaki, Gunma 370-0013, Japan
– sequence: 12
  givenname: Aya
  surname: Kikitsu
  fullname: Kikitsu, Aya
  organization: Pharmaceutical Research Laboratories, Nippon Kayaku Co., Ltd., 3-31-12, Shimo, Kita-ku, Tokyo 115-0042, Japan
– sequence: 13
  givenname: Takashi
  surname: Kumagai
  fullname: Kumagai, Takashi
  organization: Pharmaceutical Science and Technology Labs, Pharmaceutical Technology, Astellas Pharma Inc., 2-5-3 Tokodai, Tsukuba, Ibaraki 300-2698, Japan
– sequence: 14
  givenname: Naoki
  surname: Mori
  fullname: Mori, Naoki
  organization: Supply Chain Management Division, Pharmaceutical Research Department, Production Technology, Mitsubishi Tanabe Pharma Corporation, 3-16-89, Kashima, Yodogawa-ku, Osaka-shi, Osaka 532-8505, Japan
– sequence: 15
  givenname: Hiroaki
  surname: Murase
  fullname: Murase, Hiroaki
  organization: Research Division, Formulation Development, Biomanufacturing Technology, JCR Pharmaceuticals Co., Ltd., 2-2-9 Murotani, Nishi-ku, Kobe, Hyogo 651-2241, Japan
– sequence: 16
  givenname: Hirotaka
  surname: Nishimura
  fullname: Nishimura, Hirotaka
  organization: Pharmaceutical Laboratory, Mochida Pharmaceutical Co., Ltd., 342 Gensuke, Fujieda, Shizuoka 426-8640, Japan
– sequence: 17
  givenname: Atsushi
  surname: Oda
  fullname: Oda, Atsushi
  organization: CMC Regulatory and Analytical R&D, Ono Pharmaceutical Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan
– sequence: 18
  givenname: Taiichiro
  surname: Ogawa
  fullname: Ogawa, Taiichiro
  organization: CMC Analysis Laboratory, Toray Research Center, Inc., 9-1, Oe-cho, Minato-ku, Nagoya, Aichi 455-8502, Japan
– sequence: 19
  givenname: Takuma
  surname: Ojima
  fullname: Ojima, Takuma
  organization: Analytical and Quality Evaluation Research Laboratories, Daiichi Sankyo Co., Ltd., 1-12-1, Shinomiya, Hiratsuka, Kanagawa 254-0014, Japan
– sequence: 20
  givenname: Shinji
  surname: Okabe
  fullname: Okabe, Shinji
  organization: Research Division, Formulation Development, Biomanufacturing Technology, JCR Pharmaceuticals Co., Ltd., 2-2-9 Murotani, Nishi-ku, Kobe, Hyogo 651-2241, Japan
– sequence: 21
  givenname: Shuntaro
  surname: Saito
  fullname: Saito, Shuntaro
  organization: Analytical and Quality Evaluation Research Laboratories, Daiichi Sankyo Co., Ltd., 1-12-1, Shinomiya, Hiratsuka, Kanagawa 254-0014, Japan
– sequence: 22
  givenname: Satoshi
  surname: Saitoh
  fullname: Saitoh, Satoshi
  organization: Pharmaceutical Technology Division, Quality Development Department, Chugai Pharma Manufacturing, 5-1, Ukima, 5-chome, Kita-ku, Tokyo 115-8543, Japan
– sequence: 23
  givenname: Hiroyuki
  surname: Suetomo
  fullname: Suetomo, Hiroyuki
  organization: Bio Process Research and Development Laboratories, Kyowa Hakko Kirin Co., Ltd., 100-1, Hagiwara-machi, Takasaki, Gunma 370-0013, Japan
– sequence: 24
  givenname: Kazuhiro
  surname: Takegami
  fullname: Takegami, Kazuhiro
  organization: CMC Analysis Laboratory, Toray Research Center, Inc., 9-1, Oe-cho, Minato-ku, Nagoya, Aichi 455-8502, Japan
– sequence: 25
  givenname: Momoko
  surname: Takeuchi
  fullname: Takeuchi, Momoko
  organization: Pharmaceutical Research Laboratories, Nippon Kayaku Co., Ltd., 3-31-12, Shimo, Kita-ku, Tokyo 115-0042, Japan
– sequence: 26
  givenname: Hidehito
  surname: Yasukawa
  fullname: Yasukawa, Hidehito
  organization: Research Division, Formulation Development, Biomanufacturing Technology, JCR Pharmaceuticals Co., Ltd., 2-2-9 Murotani, Nishi-ku, Kobe, Hyogo 651-2241, Japan
– sequence: 27
  givenname: Susumu
  surname: Uchiyama
  fullname: Uchiyama, Susumu
  organization: Department of Biotechnology, Graduate School of Engineering, Osaka University, 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan
– sequence: 28
  givenname: Akiko
  surname: Ishii-Watabe
  fullname: Ishii-Watabe, Akiko
  organization: Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-9501, Japan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30121316$$D View this record in MEDLINE/PubMed
BookMark eNp9kU9r3DAQxUVJaTZpv0APRcdevB3JK9lbekmX_CsLKaQ5i7Et7WqxJVeyt9lP0q9bOZtceggMDAPv9wbeOyMnzjtNyEcGcwZMftnNH_ttnHNg5RzSgHxDZkxwyCSw4oTMADjPcrFYnpKzGHeQFCDEO3KaA-MsZ3JG_q5822LlAw52r-n9MDYHanygFw7bQ7SRekPvx2pvo61aTX9iGGzd6kgfonUbetX6P_S2w810oGvo2m62A72rYj1Ont59pZePvQ5WuzpR1tEf2KPTUdPv1vdbDB3Wekym2NKVd9GnB2P3nrw12Eb94Xmfk4ery1-rm2x9d327ulhn9ULKIWtMgVpUojESSy5LI7gUjDec4RIKwKaoDJbLAs2SMy4WopQckRtpgCdwkZ-Tz0ffPvjfo46D6mysdcrEaT9GxWEJOQgpWZJ-epaOVacb1QfbYTiolzCToDwK6uBjDNqo2g5PGQwBbasYqKk3tVNTb2rqTUEamFD-H_ri_ir07QjpFNDe6qBi_RRzY4OuB9V4-xr-D7XxtEw
CitedBy_id crossref_primary_10_1016_j_ejpb_2023_07_018
crossref_primary_10_1007_s12247_024_09810_4
crossref_primary_10_1016_j_xphs_2019_08_009
crossref_primary_10_1021_acs_molpharmaceut_3c00859
crossref_primary_10_1016_j_xphs_2020_03_024
crossref_primary_10_1016_j_xphs_2022_08_006
crossref_primary_10_1016_j_xphs_2019_10_046
crossref_primary_10_1016_j_xphs_2022_01_016
crossref_primary_10_1016_j_xphs_2022_07_006
crossref_primary_10_1016_j_xphs_2022_10_010
crossref_primary_10_1016_j_xphs_2023_10_007
crossref_primary_10_1016_j_xphs_2024_04_011
crossref_primary_10_1007_s12247_023_09734_5
crossref_primary_10_1016_j_ijbiomac_2021_07_012
crossref_primary_10_1016_j_ejpb_2021_07_001
crossref_primary_10_1016_j_ijpharm_2025_125373
crossref_primary_10_1016_j_xphs_2019_10_034
crossref_primary_10_1016_j_xphs_2021_06_002
crossref_primary_10_1016_j_xphs_2020_01_001
crossref_primary_10_1016_j_xphs_2022_03_011
crossref_primary_10_1142_S1793545822440060
crossref_primary_10_1016_j_xphs_2021_12_011
crossref_primary_10_1016_j_xphs_2020_10_044
crossref_primary_10_1016_j_xphs_2019_10_017
crossref_primary_10_1016_j_xphs_2020_01_009
crossref_primary_10_1016_j_ijbiomac_2022_06_176
crossref_primary_10_1007_s11095_022_03170_9
crossref_primary_10_1016_j_ijpharm_2024_124778
crossref_primary_10_1016_j_ijpharm_2024_124577
crossref_primary_10_1021_acs_molpharmaceut_4c00681
crossref_primary_10_1016_j_ejpb_2023_01_017
crossref_primary_10_1016_j_ijbiomac_2023_123439
crossref_primary_10_1016_j_seppur_2023_126036
crossref_primary_10_1016_j_jpba_2019_112802
crossref_primary_10_1208_s12248_019_0384_0
crossref_primary_10_1016_j_xphs_2021_09_047
crossref_primary_10_1002_amp2_10142
crossref_primary_10_1016_j_ijpharm_2020_119704
crossref_primary_10_1007_s11095_023_03474_4
crossref_primary_10_1016_j_xphs_2021_09_021
Cites_doi 10.1002/jps.23786
10.1208/s12248-013-9522-2
10.1016/j.ijpharm.2012.04.040
10.1021/ja042898o
10.1007/s11095-011-0590-7
10.1016/S0022-3549(15)00180-X
10.1002/jps.22046
10.1007/s11095-015-1817-9
10.1002/jps.23242
10.1002/jps.23973
10.1001/jama.300.16.1887
10.1016/j.drudis.2014.09.003
10.1080/19420862.2018.1415671
10.1002/jps.23434
10.1002/jps.21719
10.1002/jps.22732
10.1208/s12248-010-9233-x
10.1002/jps.20237
10.1016/j.ejps.2013.12.014
10.1002/jps.23408
10.1002/jps.24184
10.1002/jps.23244
10.1074/jbc.M110.160457
10.1002/jps.21834
10.1016/j.xphs.2017.02.005
10.1002/jps.21530
10.1002/jps.23479
ContentType Journal Article
Copyright 2019 The Authors
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2019 The Authors
– notice: Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
DBID 6I.
AAFTH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.xphs.2018.08.006
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1520-6017
EndPage 841
ExternalDocumentID 30121316
10_1016_j_xphs_2018_08_006
S0022354918305057
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Japan
GeographicLocations_xml – name: Japan
GroupedDBID ---
-~X
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1CY
1L6
1OC
1ZS
31~
36B
3O-
3WU
4.4
457
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52W
52X
53G
5GY
5RE
5VS
66C
6I.
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A03
A8Z
AAEVG
AAFTH
AAKUH
AALRI
AAMMB
AANHP
AAOIN
AAONW
AAXUO
AAYOK
AAYWO
AAZKR
ABCQN
ABEML
ABFRF
ABIJN
ABJNI
ABMAC
ABOCM
ABPVW
ACBWZ
ACGFO
ACGFS
ACIWK
ACPRK
ACRPL
ACSCC
ACVFH
ACXQS
ACYXJ
ADBBV
ADCNI
ADIZJ
ADNMO
ADVLN
AEFGJ
AEFWE
AEIMD
AENEX
AEUPX
AFBPY
AFFNX
AFJKZ
AFPUW
AFRAH
AFTJW
AFZJQ
AGCQF
AGHFR
AGQPQ
AGXDD
AI.
AIDQK
AIDYY
AIGII
AITUG
AJAOE
AKBMS
AKRWK
AKYEP
ALAGY
ALMA_UNASSIGNED_HOLDINGS
AMBMR
AMRAJ
APXCP
ATUGU
AZBYB
BAFTC
BDRZF
BNHUX
BROTX
BRXPI
BY8
CS3
D-E
D-F
DCZOG
DPXWK
DR2
DU5
E3Z
EBD
EBS
EFKBS
EJD
EMB
EMOBN
F00
F01
F04
F5P
FDB
FEDTE
G-S
G.N
GNP
GODZA
H.T
H.X
HBH
HF~
HHY
HHZ
HOLLA
HVGLF
HX~
HZ~
IX1
J0M
JPC
KQQ
L7B
LAW
LC2
LC3
LH4
LP6
LP7
LSO
LW6
M41
M6Q
MK0
MK4
N04
N05
N9A
NF~
NNB
O9-
OIG
P2P
P2X
P4D
Q.N
Q11
QB0
QRW
R.K
RNS
ROL
RX1
RYL
SSZ
SUPJJ
SV3
UB1
UKR
UNMZH
V2E
V8K
VH1
W8V
W99
WH7
WIB
WJL
WQJ
WYUIH
XG1
XPP
XV2
Y6R
ZE2
ZGI
ZXP
~IA
~WT
AAHHS
AAYXX
ACCFJ
AEEZP
AEQDE
AIWBW
AJBDE
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c466t-df7ae5b5df6a8268f526512d21a9070ad7bfa897af9212545862aa2f6f02ae543
ISSN 0022-3549
1520-6017
IngestDate Fri Jul 11 01:13:32 EDT 2025
Mon Jul 21 05:36:45 EDT 2025
Thu Apr 24 23:08:11 EDT 2025
Tue Jul 01 02:09:31 EDT 2025
Sun Jul 20 02:20:18 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords standards
particle size
microparticle(s)
image analysis
protein aggregation
Language English
License This is an open access article under the CC BY-NC-ND license.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c466t-df7ae5b5df6a8268f526512d21a9070ad7bfa897af9212545862aa2f6f02ae543
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://dx.doi.org/10.1016/j.xphs.2018.08.006
PMID 30121316
PQID 2090305661
PQPubID 23479
PageCount 10
ParticipantIDs proquest_miscellaneous_2090305661
pubmed_primary_30121316
crossref_citationtrail_10_1016_j_xphs_2018_08_006
crossref_primary_10_1016_j_xphs_2018_08_006
elsevier_sciencedirect_doi_10_1016_j_xphs_2018_08_006
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate February 2019
2019-02-00
20190201
PublicationDateYYYYMMDD 2019-02-01
PublicationDate_xml – month: 02
  year: 2019
  text: February 2019
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of pharmaceutical sciences
PublicationTitleAlternate J Pharm Sci
PublicationYear 2019
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Fradkin, Carpenter, Randolph (bib19) 2009; 98
Ripple, Wayment, Carrier (bib30) 2011; 14
Gerhardt, Bonam, Bee, Carpenter, Randolph (bib11) 2013; 102
Zolls, Gregoritza, Tantipolphan (bib25) 2013; 102
Kirshner (bib21) 2012
Pedersen, Persson (bib22) 2014; 103
Rosenberg, Verthelyi, Cherney (bib7) 2012; 101
Strehl, Rombach-Riegraf, Diez (bib26) 2012; 29
Barnard, Rhyner, Carpenter (bib23) 2012; 101
Demeule, Messick, Shire, Liu (bib28) 2010; 12
Basu, Krishnan, Thirumangalathu, Randolph, Carpenter (bib10) 2013; 102
Krayukhina, Tsumoto, Uchiyama, Fukui (bib6) 2015; 104
Roach, Farrar, Perry (bib12) 2005; 127
Zolls, Weinbuch, Wiggenhorn (bib32) 2013; 15
Kaplon, Reichert (bib3) 2018; 10
Sharma, Oma, Pollo, Sukumar (bib27) 2010; 99
Ripple, Hu (bib33) 2016; 33
Carpenter, Randolph, Jiskoot (bib4) 2009; 98
Chi, Weickmann, Carpenter, Manning, Randolph (bib14) 2005; 94
(bib20) 2013
Cavicchi, Collett, Telikepalli, Hu, Carrier, Ripple (bib31) 2017; 106
Thirumangalathu, Krishnan, Ricci, Brems, Randolph, Carpenter (bib13) 2009; 98
Werk, Volkin, Mahler (bib29) 2014; 53
Wang, Singh, Li, Toler, King, Nema (bib9) 2012; 431
Giezen, Mantel-Teeuwisse, Straus, Schellekens, Leufkens, Egberts (bib1) 2008; 300
(bib16) 2014
(bib17) 2014
(bib18) 2007
Ripple, Dimitrova (bib24) 2012; 101
Kinch (bib2) 2015; 20
Gerhardt, McGraw, Schwartz, Bee, Carpenter, Randolph (bib5) 2014; 103
Kotarek, Stuart, De Paoli (bib8) 2016; 105
Joubert, Luo, Nashed-Samuel, Wypych, Narhi (bib15) 2011; 286
Krayukhina (10.1016/j.xphs.2018.08.006_bib6) 2015; 104
Gerhardt (10.1016/j.xphs.2018.08.006_bib11) 2013; 102
(10.1016/j.xphs.2018.08.006_bib16) 2014
Kaplon (10.1016/j.xphs.2018.08.006_bib3) 2018; 10
Thirumangalathu (10.1016/j.xphs.2018.08.006_bib13) 2009; 98
Giezen (10.1016/j.xphs.2018.08.006_bib1) 2008; 300
Carpenter (10.1016/j.xphs.2018.08.006_bib4) 2009; 98
Chi (10.1016/j.xphs.2018.08.006_bib14) 2005; 94
Barnard (10.1016/j.xphs.2018.08.006_bib23) 2012; 101
Wang (10.1016/j.xphs.2018.08.006_bib9) 2012; 431
Werk (10.1016/j.xphs.2018.08.006_bib29) 2014; 53
Demeule (10.1016/j.xphs.2018.08.006_bib28) 2010; 12
Ripple (10.1016/j.xphs.2018.08.006_bib30) 2011; 14
Gerhardt (10.1016/j.xphs.2018.08.006_bib5) 2014; 103
Kotarek (10.1016/j.xphs.2018.08.006_bib8) 2016; 105
Ripple (10.1016/j.xphs.2018.08.006_bib24) 2012; 101
Sharma (10.1016/j.xphs.2018.08.006_bib27) 2010; 99
Basu (10.1016/j.xphs.2018.08.006_bib10) 2013; 102
(10.1016/j.xphs.2018.08.006_bib20) 2013
Zolls (10.1016/j.xphs.2018.08.006_bib25) 2013; 102
Ripple (10.1016/j.xphs.2018.08.006_bib33) 2016; 33
(10.1016/j.xphs.2018.08.006_bib17) 2014
Fradkin (10.1016/j.xphs.2018.08.006_bib19) 2009; 98
Strehl (10.1016/j.xphs.2018.08.006_bib26) 2012; 29
Roach (10.1016/j.xphs.2018.08.006_bib12) 2005; 127
Pedersen (10.1016/j.xphs.2018.08.006_bib22) 2014; 103
(10.1016/j.xphs.2018.08.006_bib18) 2007
Zolls (10.1016/j.xphs.2018.08.006_bib32) 2013; 15
Rosenberg (10.1016/j.xphs.2018.08.006_bib7) 2012; 101
Kinch (10.1016/j.xphs.2018.08.006_bib2) 2015; 20
Kirshner (10.1016/j.xphs.2018.08.006_bib21) 2012
Cavicchi (10.1016/j.xphs.2018.08.006_bib31) 2017; 106
Joubert (10.1016/j.xphs.2018.08.006_bib15) 2011; 286
References_xml – volume: 101
  start-page: 140
  year: 2012
  end-page: 153
  ident: bib23
  article-title: Critical evaluation and guidance for using the coulter method for counting subvisible particles in protein solutions
  publication-title: J Pharm Sci
– volume: 104
  start-page: 527
  year: 2015
  end-page: 535
  ident: bib6
  article-title: Effects of syringe material and silicone oil lubrication on the stability of pharmaceutical proteins
  publication-title: J Pharm Sci
– volume: 102
  start-page: 429
  year: 2013
  end-page: 440
  ident: bib11
  article-title: Ionic strength affects tertiary structure and aggregation propensity of a monoclonal antibody adsorbed to silicone oil-water interfaces
  publication-title: J Pharm Sci
– volume: 101
  start-page: 3568
  year: 2012
  end-page: 3579
  ident: bib24
  article-title: Protein particles: what we know and what we do not know
  publication-title: J Pharm Sci
– volume: 15
  start-page: 1200
  year: 2013
  end-page: 1211
  ident: bib32
  article-title: Flow imaging microscopy for protein particle analysis--a comparative evaluation of four different analytical instruments
  publication-title: AAPS J
– volume: 10
  start-page: 183
  year: 2018
  end-page: 203
  ident: bib3
  article-title: Antibodies to watch in 2018
  publication-title: MAbs
– volume: 98
  start-page: 3247
  year: 2009
  end-page: 3264
  ident: bib19
  article-title: Immunogenicity of aggregates of recombinant human growth hormone in mouse models
  publication-title: J Pharm Sci
– volume: 29
  start-page: 594
  year: 2012
  end-page: 602
  ident: bib26
  article-title: Discrimination between silicone oil droplets and protein aggregates in biopharmaceuticals: a novel multiparametric image filter for sub-visible particles in microflow imaging analysis
  publication-title: Pharm Res
– volume: 53
  start-page: 95
  year: 2014
  end-page: 108
  ident: bib29
  article-title: Effect of solution properties on the counting and sizing of subvisible particle standards as measured by light obscuration and digital imaging methods
  publication-title: Eur J Pharm Sci
– volume: 101
  start-page: 3560
  year: 2012
  end-page: 3567
  ident: bib7
  article-title: Managing uncertainty: a perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins
  publication-title: J Pharm Sci
– year: 2012
  ident: bib21
  article-title: Regulatory Expectations for Analysis of Aggregates and Particles
– volume: 98
  start-page: 1201
  year: 2009
  end-page: 1205
  ident: bib4
  article-title: Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality
  publication-title: J Pharm Sci
– volume: 99
  start-page: 2628
  year: 2010
  end-page: 2642
  ident: bib27
  article-title: Quantification and characterization of subvisible proteinaceous particles in opalescent mAb formulations using micro-flow imaging
  publication-title: J Pharm Sci
– volume: 94
  start-page: 256
  year: 2005
  end-page: 274
  ident: bib14
  article-title: Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation
  publication-title: J Pharm Sci
– volume: 300
  start-page: 1887
  year: 2008
  end-page: 1896
  ident: bib1
  article-title: Safety-related regulatory actions for biologicals approved in the United States and the European Union
  publication-title: JAMA
– volume: 286
  start-page: 25118
  year: 2011
  end-page: 25133
  ident: bib15
  article-title: Classification and characterization of therapeutic antibody aggregates
  publication-title: J Biol Chem
– volume: 431
  start-page: 1
  year: 2012
  end-page: 11
  ident: bib9
  article-title: Immunogenicity of protein aggregates--concerns and realities
  publication-title: Int J Pharm
– year: 2013
  ident: bib20
  article-title: Immunogenicity Assessment for Therapeutic Protein Products (Draft Guidance)
– year: 2014
  ident: bib16
  publication-title: USP/NF Monograph <787>. Subvisible Particulate Matter in Therapeutic Protein Injections
– volume: 106
  start-page: 1499
  year: 2017
  end-page: 1507
  ident: bib31
  article-title: Variable threshold method for determining the boundaries of imaged subvisible particles
  publication-title: J Pharm Sci
– volume: 105
  start-page: 1023
  year: 2016
  end-page: 1027
  ident: bib8
  article-title: Subvisible particle content, formulation, and dose of an erythropoietin peptide mimetic product are associated with severe adverse postmarketing events
  publication-title: J Pharm Sci
– volume: 127
  start-page: 8168
  year: 2005
  end-page: 8173
  ident: bib12
  article-title: Interpretation of protein adsorption: surface-induced conformational changes
  publication-title: J Am Chem Soc
– volume: 20
  start-page: 393
  year: 2015
  end-page: 398
  ident: bib2
  article-title: An overview of FDA-approved biologics medicines
  publication-title: Drug Discov Today
– volume: 14
  start-page: 90
  year: 2011
  end-page: 96
  ident: bib30
  article-title: Standards for the optical detection of protein particles
  publication-title: Amer Pharm Rev
– year: 2007
  ident: bib18
  publication-title: United States Pharmacopeia and National Formulary (USP29- NF24)
– volume: 102
  start-page: 1434
  year: 2013
  end-page: 1446
  ident: bib25
  article-title: How subvisible particles become invisible-relevance of the refractive index for protein particle analysis
  publication-title: J Pharm Sci
– volume: 12
  start-page: 708
  year: 2010
  end-page: 715
  ident: bib28
  article-title: Characterization of particles in protein solutions: reaching the limits of current technologies
  publication-title: AAPS J
– volume: 103
  start-page: 1601
  year: 2014
  end-page: 1612
  ident: bib5
  article-title: Protein aggregation and particle formation in prefilled glass syringes
  publication-title: J Pharm Sci
– volume: 33
  start-page: 653
  year: 2016
  end-page: 672
  ident: bib33
  article-title: Correcting the relative bias of light obscuration and flow imaging particle counters
  publication-title: Pharm Res
– year: 2014
  ident: bib17
  publication-title: USP/NF Monograph <788>. Particulate Matter in Injections
– volume: 103
  start-page: 107
  year: 2014
  end-page: 114
  ident: bib22
  article-title: Unmasking translucent protein particles by improved micro-flow imaging algorithms
  publication-title: J Pharm Sci
– volume: 102
  start-page: 852
  year: 2013
  end-page: 865
  ident: bib10
  article-title: IgG1 aggregation and particle formation induced by silicone-water interfaces on siliconized borosilicate glass beads: a model for siliconized primary containers
  publication-title: J Pharm Sci
– volume: 98
  start-page: 3167
  year: 2009
  end-page: 3181
  ident: bib13
  article-title: Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution
  publication-title: J Pharm Sci
– volume: 103
  start-page: 107
  issue: 1
  year: 2014
  ident: 10.1016/j.xphs.2018.08.006_bib22
  article-title: Unmasking translucent protein particles by improved micro-flow imaging algorithms
  publication-title: J Pharm Sci
  doi: 10.1002/jps.23786
– volume: 15
  start-page: 1200
  issue: 4
  year: 2013
  ident: 10.1016/j.xphs.2018.08.006_bib32
  article-title: Flow imaging microscopy for protein particle analysis--a comparative evaluation of four different analytical instruments
  publication-title: AAPS J
  doi: 10.1208/s12248-013-9522-2
– year: 2007
  ident: 10.1016/j.xphs.2018.08.006_bib18
– year: 2014
  ident: 10.1016/j.xphs.2018.08.006_bib16
– volume: 431
  start-page: 1
  issue: 1-2
  year: 2012
  ident: 10.1016/j.xphs.2018.08.006_bib9
  article-title: Immunogenicity of protein aggregates--concerns and realities
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2012.04.040
– volume: 127
  start-page: 8168
  issue: 22
  year: 2005
  ident: 10.1016/j.xphs.2018.08.006_bib12
  article-title: Interpretation of protein adsorption: surface-induced conformational changes
  publication-title: J Am Chem Soc
  doi: 10.1021/ja042898o
– volume: 29
  start-page: 594
  issue: 2
  year: 2012
  ident: 10.1016/j.xphs.2018.08.006_bib26
  article-title: Discrimination between silicone oil droplets and protein aggregates in biopharmaceuticals: a novel multiparametric image filter for sub-visible particles in microflow imaging analysis
  publication-title: Pharm Res
  doi: 10.1007/s11095-011-0590-7
– volume: 105
  start-page: 1023
  issue: 3
  year: 2016
  ident: 10.1016/j.xphs.2018.08.006_bib8
  article-title: Subvisible particle content, formulation, and dose of an erythropoietin peptide mimetic product are associated with severe adverse postmarketing events
  publication-title: J Pharm Sci
  doi: 10.1016/S0022-3549(15)00180-X
– volume: 99
  start-page: 2628
  issue: 6
  year: 2010
  ident: 10.1016/j.xphs.2018.08.006_bib27
  article-title: Quantification and characterization of subvisible proteinaceous particles in opalescent mAb formulations using micro-flow imaging
  publication-title: J Pharm Sci
  doi: 10.1002/jps.22046
– volume: 33
  start-page: 653
  issue: 3
  year: 2016
  ident: 10.1016/j.xphs.2018.08.006_bib33
  article-title: Correcting the relative bias of light obscuration and flow imaging particle counters
  publication-title: Pharm Res
  doi: 10.1007/s11095-015-1817-9
– volume: 101
  start-page: 3568
  issue: 10
  year: 2012
  ident: 10.1016/j.xphs.2018.08.006_bib24
  article-title: Protein particles: what we know and what we do not know
  publication-title: J Pharm Sci
  doi: 10.1002/jps.23242
– volume: 103
  start-page: 1601
  issue: 6
  year: 2014
  ident: 10.1016/j.xphs.2018.08.006_bib5
  article-title: Protein aggregation and particle formation in prefilled glass syringes
  publication-title: J Pharm Sci
  doi: 10.1002/jps.23973
– year: 2014
  ident: 10.1016/j.xphs.2018.08.006_bib17
– volume: 14
  start-page: 90
  year: 2011
  ident: 10.1016/j.xphs.2018.08.006_bib30
  article-title: Standards for the optical detection of protein particles
  publication-title: Amer Pharm Rev
– volume: 300
  start-page: 1887
  issue: 16
  year: 2008
  ident: 10.1016/j.xphs.2018.08.006_bib1
  article-title: Safety-related regulatory actions for biologicals approved in the United States and the European Union
  publication-title: JAMA
  doi: 10.1001/jama.300.16.1887
– volume: 20
  start-page: 393
  issue: 4
  year: 2015
  ident: 10.1016/j.xphs.2018.08.006_bib2
  article-title: An overview of FDA-approved biologics medicines
  publication-title: Drug Discov Today
  doi: 10.1016/j.drudis.2014.09.003
– volume: 10
  start-page: 183
  issue: 2
  year: 2018
  ident: 10.1016/j.xphs.2018.08.006_bib3
  article-title: Antibodies to watch in 2018
  publication-title: MAbs
  doi: 10.1080/19420862.2018.1415671
– volume: 102
  start-page: 852
  issue: 3
  year: 2013
  ident: 10.1016/j.xphs.2018.08.006_bib10
  article-title: IgG1 aggregation and particle formation induced by silicone-water interfaces on siliconized borosilicate glass beads: a model for siliconized primary containers
  publication-title: J Pharm Sci
  doi: 10.1002/jps.23434
– volume: 98
  start-page: 3167
  issue: 9
  year: 2009
  ident: 10.1016/j.xphs.2018.08.006_bib13
  article-title: Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution
  publication-title: J Pharm Sci
  doi: 10.1002/jps.21719
– year: 2013
  ident: 10.1016/j.xphs.2018.08.006_bib20
– volume: 101
  start-page: 140
  issue: 1
  year: 2012
  ident: 10.1016/j.xphs.2018.08.006_bib23
  article-title: Critical evaluation and guidance for using the coulter method for counting subvisible particles in protein solutions
  publication-title: J Pharm Sci
  doi: 10.1002/jps.22732
– volume: 12
  start-page: 708
  issue: 4
  year: 2010
  ident: 10.1016/j.xphs.2018.08.006_bib28
  article-title: Characterization of particles in protein solutions: reaching the limits of current technologies
  publication-title: AAPS J
  doi: 10.1208/s12248-010-9233-x
– volume: 94
  start-page: 256
  issue: 2
  year: 2005
  ident: 10.1016/j.xphs.2018.08.006_bib14
  article-title: Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation
  publication-title: J Pharm Sci
  doi: 10.1002/jps.20237
– volume: 53
  start-page: 95
  year: 2014
  ident: 10.1016/j.xphs.2018.08.006_bib29
  article-title: Effect of solution properties on the counting and sizing of subvisible particle standards as measured by light obscuration and digital imaging methods
  publication-title: Eur J Pharm Sci
  doi: 10.1016/j.ejps.2013.12.014
– volume: 102
  start-page: 429
  issue: 2
  year: 2013
  ident: 10.1016/j.xphs.2018.08.006_bib11
  article-title: Ionic strength affects tertiary structure and aggregation propensity of a monoclonal antibody adsorbed to silicone oil-water interfaces
  publication-title: J Pharm Sci
  doi: 10.1002/jps.23408
– volume: 104
  start-page: 527
  issue: 2
  year: 2015
  ident: 10.1016/j.xphs.2018.08.006_bib6
  article-title: Effects of syringe material and silicone oil lubrication on the stability of pharmaceutical proteins
  publication-title: J Pharm Sci
  doi: 10.1002/jps.24184
– volume: 101
  start-page: 3560
  issue: 10
  year: 2012
  ident: 10.1016/j.xphs.2018.08.006_bib7
  article-title: Managing uncertainty: a perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins
  publication-title: J Pharm Sci
  doi: 10.1002/jps.23244
– volume: 286
  start-page: 25118
  issue: 28
  year: 2011
  ident: 10.1016/j.xphs.2018.08.006_bib15
  article-title: Classification and characterization of therapeutic antibody aggregates
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M110.160457
– volume: 98
  start-page: 3247
  issue: 9
  year: 2009
  ident: 10.1016/j.xphs.2018.08.006_bib19
  article-title: Immunogenicity of aggregates of recombinant human growth hormone in mouse models
  publication-title: J Pharm Sci
  doi: 10.1002/jps.21834
– volume: 106
  start-page: 1499
  issue: 6
  year: 2017
  ident: 10.1016/j.xphs.2018.08.006_bib31
  article-title: Variable threshold method for determining the boundaries of imaged subvisible particles
  publication-title: J Pharm Sci
  doi: 10.1016/j.xphs.2017.02.005
– volume: 98
  start-page: 1201
  issue: 4
  year: 2009
  ident: 10.1016/j.xphs.2018.08.006_bib4
  article-title: Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality
  publication-title: J Pharm Sci
  doi: 10.1002/jps.21530
– year: 2012
  ident: 10.1016/j.xphs.2018.08.006_bib21
– volume: 102
  start-page: 1434
  issue: 5
  year: 2013
  ident: 10.1016/j.xphs.2018.08.006_bib25
  article-title: How subvisible particles become invisible-relevance of the refractive index for protein particle analysis
  publication-title: J Pharm Sci
  doi: 10.1002/jps.23479
SSID ssj0006055
Score 2.4672651
Snippet The evaluation of subvisible particles, including protein aggregates, in therapeutic protein products has been of great interest for both pharmaceutical...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 832
SubjectTerms image analysis
Immunoglobulins, Intravenous - chemistry
Japan
Light
microparticle(s)
Optical Imaging
Particle Size
Protein Aggregates
protein aggregation
Technology, Pharmaceutical
Title Collaborative Study for Analysis of Subvisible Particles Using Flow Imaging and Light Obscuration: Experiences in Japanese Biopharmaceutical Consortium
URI https://dx.doi.org/10.1016/j.xphs.2018.08.006
https://www.ncbi.nlm.nih.gov/pubmed/30121316
https://www.proquest.com/docview/2090305661
Volume 108
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswECXc9NJL0b3uhilQ5KLI0EpLvQVBDDdwEqOQAd8EyhIRZbEMW2rr_Eh_oZ_ZIaktsROkvQgGQcqC3tNwZjgLIV9o7FNmJVSfRY6jO7il6B7ntt6PbNuMTRYnpkhwPj6hw4lzNHWnnc6fVtRSkUe92fXWvJL_QRXHEFeRJfsPyNY3xQH8jfjiFRHG64MwPmhA_KFCAlX4ZbvSCEoGkT8uEqTGVRScpgIFBpfZT-3blepTJBzoI2Gpa6coSoplHfXRFEOWobNHuLuKrpWii-Xi7IZDXDT_RG0-Las7bKq8t-aXu29znJSus5VsMqwdsxXLs9r9c5ZGTKm5w3SZXWSN3Fyya9U9XNu_SJf1HhNkKLwKScYkXxVZ27kh8qnqQJFSHgvr1lDpnb1ky1glxA2vxVarJZI95T_d2CqU1-K892shy7abnizlamypy31yGg4mo1EYHE6DR-SxhQaJNN6_N4XK0Ch0ZWXe8tHK9CwVSXj7H-5Sge4ycaSqEzwjT0vAYF-x5TnpJPMXZHeswFvvQdDk7K32YBfGTfnz9Uvy-wYrQbISkJVQsRIyDg0roWYlSFaCYCWUrARkJUhWQouVX6HFSUjnUHESNjgJDSdfkcngMDgY6mX7D33mUJrrMe-zxI3cmFOGRrDHRScH04otk_m4UbG4H3Hm-X3GfdS_xAEwtRizOOWGhQsd-zXZmWfz5C0B1-Kz2OonkYH6NiqoHt6C2zxm1LZ86vldYlaIhLOyNr5o0XIZVkGQ56FAMRQohqJvq0G7RKvXLFRlmHtnuxXQYfl1KZ01RD7eu-5zxYoQBb84zcMXmhViki_tf2p2yRtFl_o5bFmp0aTvHrD6PXnSfHkfyE6-LJKPqGjn0SfJ8b9Oatxq
linkProvider Wiley-Blackwell
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Collaborative+Study+for+Analysis+of+Subvisible+Particles+Using+Flow+Imaging+and+Light+Obscuration%3A+Experiences+in+Japanese+Biopharmaceutical+Consortium&rft.jtitle=Journal+of+pharmaceutical+sciences&rft.au=Kiyoshi%2C+Masato&rft.au=Shibata%2C+Hiroko&rft.au=Harazono%2C+Akira&rft.au=Torisu%2C+Tetsuo&rft.date=2019-02-01&rft.issn=1520-6017&rft.eissn=1520-6017&rft.volume=108&rft.issue=2&rft.spage=832&rft_id=info:doi/10.1016%2Fj.xphs.2018.08.006&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-3549&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-3549&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-3549&client=summon